Head to Head Review: GeneLink (OTCMKTS:GNLKQ) and Viridian Therapeutics (NASDAQ:VRDN)

Viridian Therapeutics (NASDAQ:VRDN) and GeneLink (OTCMKTS:GNLKQ) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Viridian Therapeutics and GeneLink’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-85,127.16%	-70.12%	-41.49%
GeneLink	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Viridian Therapeutics and GeneLink, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	0	3	9	0	2.75
GeneLink	0	0	0	0	0.00

Viridian Therapeutics currently has a consensus price target of $35.70, indicating a potential upside of 109.26%. Given Viridian Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Viridian Therapeutics is more favorable than GeneLink.

Earnings & Valuation

This table compares Viridian Therapeutics and GeneLink”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$310,000.00	4,359.11	-$237.73 million	($4.31)	-3.96
GeneLink	N/A	N/A	N/A	N/A	N/A

GeneLink has lower revenue, but higher earnings than Viridian Therapeutics.

Summary

Viridian Therapeutics beats GeneLink on 4 of the 7 factors compared between the two stocks.

About Viridian Therapeutics

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

About GeneLink

GeneLink, Inc. offers 12-gene DNA assessment services. The company also provides health custom supplements. In addition, it formulates a line of skin care products. The company was founded in 1994 and is based in Orlando, Florida.